🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Rene Costello

National Institutes of Health

ORCID: 0000-0002-2386-8019

Also affiliated with National Cancer Institute, Center for Cancer Research

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

3in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Supplementary Figure from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

(2023)10.1158/1078-0432.22486571
Top 100%
0DataRank
Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more

Papers

Driven by 18 papers — median percentile 0. Top paper: “Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors”.

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

Journal of Clinical Oncology(2020)10.1200/jco.20.01652
N/A
3.5DataRank · unranked
138 citations

Rosa Nadal, Daniel M. Girardi, Scot A. Niglio, Lisa Ley, Lisa M. Cordes +30 more

Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial

The Lancet Oncology(2020)10.1016/s1470-2045(20)30202-3
N/A
3.0DataRank · unranked
89 citations

Rosa Nadal, Yusuke Tomita, Nicole N. Davarpanah, Lisa M. Cordes, Seth M. Steinberg +27 more

Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3726
N/A
1.1DataRank · unranked
24 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo Lara, Sumanta K. Pal +30 more

Ipilimumab challenge/re-challenge in metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors treated with cabozantinib+nivolumab (CaboNivo) or cabozantinib+nivolumab+ipilimumab (CaboNivoIpi).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5039
N/A
0DataRank · unranked
3 citations

Daniel M. Girardi, Amir Mortazavi, Primo N. Lara, Sumanta K. Pal, Biren Saraiya +15 more

Phase I expansion study of cabozantinib plus nivolumab (CaboNivo) in metastatic urothelial carcinoma (mUC) patients (pts) with progressive disease following immune checkpoint inhibitor (ICI) therapy.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5037
N/A
0DataRank · unranked
2 citations

Scot A. Niglio, Amir Mortazavi, Primo Lara, Sumanta K. Pal, Biren Saraiya +15 more

Autocrine Signaling by Receptor Tyrosine Kinases in Urothelial Carcinoma of the Bladder

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.10.15.341206
N/A
0DataRank · unranked
0 citations

Molly M. Lee, Dinuka M. De Silva, Arpita Singha Roy, Cara E. Wright, Tiffany K. Wong +7 more

Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2480
N/A
0DataRank · unranked
27 citations

Shivaani Kummar, James Hu, Kristen Ganjoo, Warren A. Chow, Khanh T. Do +17 more

Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder

PLoS ONE(2021)10.1371/journal.pone.0241766
N/A
0DataRank · unranked
7 citations

Molly M. Lee, Dinuka M. De Silva, Arpita Singha Roy, Cara E. Wright, Tiffany K. Wong +7 more

Final results from a phase I trial and expansion cohorts of cabozantinib and nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) for metastatic genitourinary tumors.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.3
N/A
0DataRank · unranked
9 citations

Daniel M. Girardi, Scot A. Niglio, Rosa Maria Nadal, Lisa M. Cordes, Seth M. Steinberg +15 more

A phase I study of bintrafusp alfa (M7824) and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in adults with metastatic non-prostate genitourinary malignancies.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps4599
N/A
0DataRank · unranked
4 citations

Daniel M. Girardi, Lisa M. Cordes, Lisa Ley, Marissa Mallek, Olena Sierra Ortiz +15 more

A pilot clinical trial of genomic-based therapy assignment with co-expression extrapolation (COXEN) in advanced/metastatic urothelial carcinoma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.452
N/A
0DataRank · unranked
0 citations

Rosa Maria Nadal, Lisa M. Cordes, Seth M. Steinberg, Nicole N. Davarpanah, Rene Costello +12 more

Supplementary Figure from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

(2023)10.1158/1078-0432.22486571
Top 100%
0DataRank
Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more

Supplementary Figure from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

Figshare(2023)10.1158/1078-0432.22486556.v1
Top 100%
0DataRank
Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more

Data from Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer

(2023)10.1158/1078-0432.c.6529986
N/A
0DataRank · unranked
0 citations

Tiziano Pramparo, Amir Mortazavi, Scot A. Niglio, Joseph D. Schonhoft, Adam Jendrisak +26 more

Data from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

(2023)10.1158/1078-0432.c.6532346.v1
Top 100%
0DataRank
Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more

Final results from a phase 1 trial and expansion cohorts of cabozantinib and nivolumab alone or with ipilimumab for advanced/metastatic genitourinary tumors

Research Square(2023)10.21203/rs.3.rs-2924051/v1
N/A
0DataRank · unranked
0 citations

Scot A. Niglio, Rosa Nadal, Andre R. Kydd, Nicholas I. Simon, Lisa Ley +36 more

Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2891
N/A
0DataRank · unranked
48 citations

Tiziano Pramparo, Amir Mortazavi, Scot A. Niglio, Joseph D. Schonhoft, Adam Jendrisak +26 more

Serum microRNA profiles among dioxin exposed veterans with monoclonal gammopathy of undetermined significance

Journal of Toxicology and Environmental Health(2020)10.1080/15287394.2020.1749919
N/A
0DataRank · unranked
7 citations

Youn K. Shim, Joel Michalek, Emily Barber, Layla M. Saleh, Byeong Yeob Choi +8 more